Cross Culture Adaptation Validity and Reliability of Arabic Version of Cornell Muscloskeletal Discomfort Questionnaire
Launched by SARA MORTADA MOHAMED · Jul 23, 2024
Trial Information
Current as of November 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is about translating and testing an Arabic version of the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ), a short survey that asks adults about aches, pains, or discomfort in different parts of the body over the past week. The goal is to see if the Arabic version is easy to understand and reliable for research purposes. This is observational work (no medical treatment) and researchers will check how well the questionnaire works before using it more broadly.
Anyone 18–60 years old who speaks Arabic and can read and fill out forms is invited if they work in a sedentary office job or in standing work. Both men and women can participate. Exclusions include cognitive problems or any condition that would make filling out the survey difficult, plus some medical conditions like inflammatory rheumatic diseases, neurological or psychiatric disorders. About 540 people are planned to take part, and the study is being run at Cairo University in Egypt. Participants will complete a 54-item questionnaire, which takes about 15 minutes. Results aren’t available yet; the study aims to confirm that the Arabic CMDQ is valid and reliable for measuring musculoskeletal discomfort.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Male and female
- • Being sedentary office workers
- • Being standing workers .Being literate and speaking Arabic. .Patients were aged from 18 to 60 years old.
- Exclusion Criteria:
- • Inability to complete the form due to cognitive impairment. .Individuals who were unable or unwilling to complete study outcomes or provide informed consent.
- • Systematic inflammatory rheumatic diseases .Neurological conditions. .Psychiatric disorders.
About Sara Mortada Mohamed
Sara Mortada Mohamed is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in healthcare and a focus on innovative therapeutic solutions, she leads initiatives that prioritize rigorous study design, ethical standards, and regulatory compliance. Her strategic approach fosters collaboration among multidisciplinary teams, ensuring the efficient execution of clinical trials while maintaining the highest quality of data integrity and participant safety. Through her leadership, she aims to contribute to the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dokki, Giza, Egypt
Patients applied
Trial Officials
haitham El Hafez, prof
Study Director
cairo university ,egypt
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported